Raily Aesthetic Medicine International Holdings Limited provided unaudited consolidated earnings guidance for the six months ended June 30, 2021. For the six months, the Board expects the Group to record a revenue of approximately RMB 91 million for the six months ended 30 June 2021, representing a significant increase of approximately 54% as compared to the revenue of approximately RMB 59 million in the same period last year and; the Board expects the Group to record a loss attributable to the shareholders of the parent of approximately RMB 5 million for the six months ended 30 June 2021, representing a decrease of approximately 58% as compared to the loss attributable to the shareholders of the parent of approximately RMB 12 million in the same period last year. The Board considers that reasons for the significant increase in revenue and the decrease in loss recorded by the Group are as follows: (i) the Board expects the Group to record a revenue of approximately RMB 91 million for the six months ended 30 June 2021, representing a significant increase of approximately 54% as compared to the revenue of approximately RMB 59 million in the same period last year and; (ii) the Board expects the Group to record a loss attributable to the shareholders of the parent of approximately RMB 5 million for the six months ended 30 June 2021, representing a decrease of approximately 58% as compared to the loss attributable to the shareholders of the parent of approximately RMB 12 million in the same period last year. The Board considers that reasons for the significant increase in revenue and the decrease in loss recorded by the Group are as follows: i) Although various measures have been taken to control COVID-19 pandemic in the PRC, the pandemic still had an impact on the Group's operation. For example, the operation of Ruian Raily Medical Beauty Hospital Co. Ltd., a subsidiary of the Company, has been temporarily suspended for half a month in June 2021 due to the pandemic; ii) The Group increased promoting and marketing activities to increase customer flow and restore clients' enthusiasm for aesthetic surgery services so as to enhance the Group's brand awareness and prepare for sales in the second half; iii) The Group reduced the professional fee for the six months ended 30 June 2021 by RMB 5 million as compared to the same period last year and; iv) The proceeds raised from the listing of the Company's securities on the Stock Exchange of Hong Kong Limited are denominated in Hong Kong dollars, and incurred an exchange loss of approximately RMB 1 million for the six months ended 30 June 2021.